A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer

Annals of Oncology

Volumn 13, Issue 8, 2002, Pages 1220-1224

  Miller, K D ^a   Gradishar, W ^b   Schuchter, L ^c   Sparano, J A ^d   Cobleigh, M ^e   Robert, N ^f   Rasmussen, H ^g   Sledge, G W ^a  

^a INDIANA UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f INOVA FAIRFAX HOSPITAL   (United States)

^g British Biotech Inc   (United States)

Author keywords

Angiogenesis; Breast cancer; Metalloproteinase; Metalloproteinase inhibitor

Indexed keywords

CYCLOSPORIN; DOXORUBICIN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXICITY; WORLD HEALTH ORGANIZATION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG ANTAGONISM; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PATHOLOGY; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036668663     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf199     Document Type: Article

References (21)

1. Metalloproteinases and their inhibitors in matrix remodeling
2. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production
3. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue
4. r 92 000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma
5. r 92 000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer
6. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
7. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
8. Marimastat: The clinical development of a matrix metalloproteinase inhibitor
9. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice
10. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
11. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
12. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
13. Phase IB study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer
14. Phase I/+ pharmacokinetic evaluation of marimastat in patients with advanced prostate cancer: Identification of the biologically active dose
15. Development of matrix metalloproteinase inhibitors in cancer therapy
16. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers
17. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
18. A randomized double-blind placebo controlled study of marimastat in patients with inoperable gastric adenocarcinoma
19. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
20. A multicenter, randomized, double-blind, placebo controlled trial of marimastat in patients with glioblastoma multiforme or gliosarcoma following completion of conventional, first-line treatment
21. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer following response to first-line chemotherapy: An NCIC-CTG and EORTC study